Navigation Links
Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery

eeding rates were 0.6% and 0.5%, and any bleeding rates were 4.9% and 4.8%, respectively. The RECORD3 trial demonstrated superior efficacy of rivaroxaban versus enoxaparin, with similarly low bleeding rates, in patients undergoing TKR.

Head of Global Development Dr. Kemal Malik, a member of Bayer HealthCare Executive Committee and management board member of Bayer Schering Pharma, commented: "Based on the data we have generated, rivaroxaban shows great promise that it could set a new standard of care in thromboembolic disease as a new benchmark for balancing safety and efficacy in anticoagulation. We hope that the clinical trials will continue to demonstrate the compelling efficacy and safety profile for rivaroxaban, while also demonstrating its utility in both the hospital and home settings without the need for routine monitoring."

The trade name of rivaroxaban is expected to be Xarelto®, pending health authority approval.

Additional Phase III results of the ongoing RECORD program are expected to be available during H2 2007.

Unmet Needs in Venous Thromboembolism (VTE) VTE is a type of thromboembolic disease that affects approximately 6.5 million people worldwide annually. Thromboembolic disease, which is caused by the obstruction of a blood vessel by a blood clot, is a leading cause of global mortality and a concern for many patient populations, including those with atrial fibrillation at risk for stroke; those at risk for acute myocardial infarction (heart attack); those undergoing orthopaedic surgery at risk for developing DVT and PE; and hospitalized, medically ill patients immobilized by cancer, congestive heart failure, acute respiratory disease, or other illnesses.

About Rivaroxaban (Xarelto®) Phase IIb data - presented at ISTH in 2005, and published in the Journal of Thrombosis and Haemostasis in 2005 and 2006, and the additional once-daily ODIXa HIP study published in Circulation in 2006 - indicate that rivaroxaban
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:7/10/2014)... Calif. , July 10, 2014 Integrated ... leader in advanced memory and analog IC solutions, today ... on Thursday, July 24, 2014, at 7:00 a.m. Pacific ... financial results for the fiscal 2014 third quarter ended ... call via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific ...
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
Breaking Medicine Technology:
... Calif., Oct. 10 Amgen (Nasdaq:  AMGN) today ... pivotal Phase 3 trials comparing denosumab to Zometa® ... the prevention of skeletal related events (SREs) in ... separate analyses, denosumab demonstrated a clinically meaningful, consistent ...
... Oct. 8 The American Dental Association (ADA) has ... ), the largest provider of health care products and ... at $860,000 to students in the Community Dental Health ... initially for hands-on clinical training in the program, which ...
Cached Medicine Technology:Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 2Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 3Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 4Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 5Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 6Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 7Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 8Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 9Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa® 10Henry Schein Inc. Donates Equipment to ADA Community Dental Health Coordinator Pilot Program 2Henry Schein Inc. Donates Equipment to ADA Community Dental Health Coordinator Pilot Program 3
(Date:7/13/2014)... TX (PRWEB) July 13, 2014 The Pearland, ... children ranging in age from four months to 12 years ... and karate classes to birthday parties and Summer Camps, is ... Little Gym of Pearland after spending over six ... of roles, including Gym Director. , Berry has over ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular suppliers of ... its new range of elegant Quinceanera dresses . ... discounted prices. Worldwide clients can enjoy this special offer ... online shop, there are plenty of beautiful dresses for ... materials. MyDressCity.com’s hot items are prom gowns, bridesmaid gowns, ...
(Date:7/13/2014)... 13, 2014 According to the Kidney Disease ... step by step guide on what to do to eliminate ... quickly. Vkool writes in its review that readers can easily ... to revitalize their kidney health. Vkool also informs in its ... reverse their damaged kidney functions naturally. The book consists of ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today that they will ... Senior Living Community in Palatine, IL. The group, called “New ... Wednesdays of every month. This group will begin on ... 55 S. Greeley St. Palatine, IL 60067. It is ... for the group. , “A grief support group is ...
(Date:7/12/2014)... 13, 2014 According to the new ... Systems, Airborne Systems, and Naval Systems) - Global Forecasts ... Security and Surveillance Radar market are estimated to be ... a CAGR of 5.97% to reach $8.61 billion by ... with 47 figures spread through 161 pages and in-depth ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4
... a startling find. Around 75 percent of whites or those ... of developing heart diseases. And that’s not all. These genes ... diabetes. ,The findings, made by two independent groups of ... even if they do not have clear risk factors such as ...
... American doctor has threatened to mobilise US congressmen and senators ... Information (RTI) Act in a case relating to his crusade ... Saha, whose wife died of alleged wrongful treatment in India ... my senators and congressmen in US and will ask them ...
... Human Resource Development in collaboration with National AIDS Control ... Adolescence Education Programme (AEP) which is being implemented by ... ,The Programme is aimed at the ... of the major concerns, i.e. process of growing up ...
... that can enable the blind to hear what they cannot see ... texts through an embedded system and converts them into voice that ... can only read text, but later it is likely to pick ... that took six months to develop the device and the software ...
... to detect epidemic diseases has entered the phase of clinical ... methods that rely on antigen or antibody test, the new ... DNA or RNA, to confirm epidemic diseases such as hepatitis ... Centre of US National Institutes of Health (NIH). ...
... and women who consumed higher levels of calcium and vitamin ... brain lesions, regions of damage// that can increase risk of ... Payne and her co-investigators from Duke and the University of ... men and women (79 men, 153 women) between the ages ...
Cached Medicine News:Health News:Gene Mutations Leave Caucasians Prone To Heart Diseases And Diabetes 2Health News:NRI Threatens to Move US Congress for Justice in India 2Health News:Higher Intake of Calcium and Vitamin D Linked With Brain Lesions in Older People 2
... The Asnis III™ Cannulated Screw System has ... and TCS Systems and combined them to ... screws in both titanium and stainless steel. ... System is designed to optimize surgical outcomes ...
The 6.5mm cannulated cancellous ACE SCFE Screw is specifically designed for the treatment of slipped capital femoral epiphysis. The ACE SCFE Screw simplifies insertion and facilitates removal....
... a wide variety of cannulated screw products. ... partially threaded and fully threaded versions. , ... and 7.0 mm products. These incorporate innovative ... a little easier. Ratchet screwdrivers have proven ...
Biomet® Arthrodesis Nail indications include: , Failed external fixation , Aseptic failed total knee arthroplasty , Periarticular fractures where repair is not possible , Limb salvage in tumor...
Medicine Products: